---
document_datetime: 2025-12-02 07:05:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/onbevzi.html
document_name: onbevzi.html
version: success
processing_time: 0.1106575
conversion_datetime: 2025-12-28 09:50:00.128072
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Onbevzi

[RSS](/en/individual-human-medicine.xml/67392)

##### Withdrawn

This medicine's authorisation has been withdrawn

bevacizumab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Onbevzi](#news-on)
- [Related content](#related-content-918)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 11 December 2023, the European Commission withdrew the marketing authorisation for Onbevzi (bevacizumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Samsung Bioepis NL B.V., which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Onbevzi was granted marketing authorisation in the EU on 11 January 2021 for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix. The marketing authorisation was initially valid for a 5-year period.

Onbevzi was a duplicate application to Aybintio, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Aybintio. The European Public Assessment Report (EPAR) for Onbevzi is updated to indicate that the marketing authorisation is no longer valid.

Onbevzi : EPAR - Medicine overview

Reference Number: EMA/617109/2020

English (EN) (149.23 KB - PDF)

**First published:** 05/03/2021

**Last updated:** 24/10/2024

[View](/en/documents/overview/onbevzi-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-443)

български (BG) (225.31 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/bg/documents/overview/onbevzi-epar-medicine-overview_bg.pdf)

español (ES) (150.96 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/es/documents/overview/onbevzi-epar-medicine-overview_es.pdf)

čeština (CS) (184.84 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/cs/documents/overview/onbevzi-epar-medicine-overview_cs.pdf)

dansk (DA) (149.36 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/da/documents/overview/onbevzi-epar-medicine-overview_da.pdf)

Deutsch (DE) (152.27 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/de/documents/overview/onbevzi-epar-medicine-overview_de.pdf)

eesti keel (ET) (145.05 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/et/documents/overview/onbevzi-epar-medicine-overview_et.pdf)

ελληνικά (EL) (241.86 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/el/documents/overview/onbevzi-epar-medicine-overview_el.pdf)

français (FR) (152.13 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/fr/documents/overview/onbevzi-epar-medicine-overview_fr.pdf)

hrvatski (HR) (167.4 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/hr/documents/overview/onbevzi-epar-medicine-overview_hr.pdf)

italiano (IT) (151.12 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/it/documents/overview/onbevzi-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (192.44 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/lv/documents/overview/onbevzi-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (179.88 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/lt/documents/overview/onbevzi-epar-medicine-overview_lt.pdf)

magyar (HU) (166.2 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/hu/documents/overview/onbevzi-epar-medicine-overview_hu.pdf)

Malti (MT) (185.07 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/mt/documents/overview/onbevzi-epar-medicine-overview_mt.pdf)

Nederlands (NL) (151.23 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/nl/documents/overview/onbevzi-epar-medicine-overview_nl.pdf)

polski (PL) (181.93 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/pl/documents/overview/onbevzi-epar-medicine-overview_pl.pdf)

português (PT) (150.99 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/pt/documents/overview/onbevzi-epar-medicine-overview_pt.pdf)

română (RO) (178.12 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/ro/documents/overview/onbevzi-epar-medicine-overview_ro.pdf)

slovenčina (SK) (176.5 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sk/documents/overview/onbevzi-epar-medicine-overview_sk.pdf)

slovenščina (SL) (168.86 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sl/documents/overview/onbevzi-epar-medicine-overview_sl.pdf)

Suomi (FI) (148.14 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/fi/documents/overview/onbevzi-epar-medicine-overview_fi.pdf)

svenska (SV) (148.62 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sv/documents/overview/onbevzi-epar-medicine-overview_sv.pdf)

Onbevzi : EPAR - Risk-management-plan summary

English (EN) (77.8 KB - PDF)

**First published:** 05/03/2021

**Last updated:** 24/10/2024

[View](/en/documents/rmp-summary/onbevzi-epar-risk-management-plan-summary_en.pdf)

## Product information

Onbevzi : EPAR - Product information

English (EN) (14.38 MB - PDF)

**First published:** 05/03/2021

**Last updated:** 24/10/2024

[View](/en/documents/product-information/onbevzi-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-392)

български (BG) (5.45 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/bg/documents/product-information/onbevzi-epar-product-information_bg.pdf)

español (ES) (4.12 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/es/documents/product-information/onbevzi-epar-product-information_es.pdf)

čeština (CS) (5.11 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/cs/documents/product-information/onbevzi-epar-product-information_cs.pdf)

dansk (DA) (5.13 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/da/documents/product-information/onbevzi-epar-product-information_da.pdf)

Deutsch (DE) (5.06 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/de/documents/product-information/onbevzi-epar-product-information_de.pdf)

eesti keel (ET) (3.68 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/et/documents/product-information/onbevzi-epar-product-information_et.pdf)

ελληνικά (EL) (12.72 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/el/documents/product-information/onbevzi-epar-product-information_el.pdf)

français (FR) (4.72 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/fr/documents/product-information/onbevzi-epar-product-information_fr.pdf)

hrvatski (HR) (4.08 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/hr/documents/product-information/onbevzi-epar-product-information_hr.pdf)

íslenska (IS) (4.16 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/is/documents/product-information/onbevzi-epar-product-information_is.pdf)

italiano (IT) (5.05 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/it/documents/product-information/onbevzi-epar-product-information_it.pdf)

latviešu valoda (LV) (4.99 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/lv/documents/product-information/onbevzi-epar-product-information_lv.pdf)

lietuvių kalba (LT) (4.3 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/lt/documents/product-information/onbevzi-epar-product-information_lt.pdf)

magyar (HU) (5.1 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/hu/documents/product-information/onbevzi-epar-product-information_hu.pdf)

Malti (MT) (5.78 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/mt/documents/product-information/onbevzi-epar-product-information_mt.pdf)

Nederlands (NL) (3.87 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/nl/documents/product-information/onbevzi-epar-product-information_nl.pdf)

norsk (NO) (4.08 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/no/documents/product-information/onbevzi-epar-product-information_no.pdf)

polski (PL) (4.51 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/pl/documents/product-information/onbevzi-epar-product-information_pl.pdf)

português (PT) (4.04 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/pt/documents/product-information/onbevzi-epar-product-information_pt.pdf)

română (RO) (4.49 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/ro/documents/product-information/onbevzi-epar-product-information_ro.pdf)

slovenčina (SK) (4.18 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sk/documents/product-information/onbevzi-epar-product-information_sk.pdf)

slovenščina (SL) (4.49 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sl/documents/product-information/onbevzi-epar-product-information_sl.pdf)

Suomi (FI) (4.14 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/fi/documents/product-information/onbevzi-epar-product-information_fi.pdf)

svenska (SV) (3.96 MB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sv/documents/product-information/onbevzi-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0005 11/12/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Onbevzi : EPAR - All authorised presentations

English (EN) (48.57 KB - PDF)

**First published:** 05/03/2021

**Last updated:** 24/10/2024

[View](/en/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-188)

български (BG) (76.5 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/bg/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.36 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/es/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_es.pdf)

čeština (CS) (65.23 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/cs/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (44.39 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/da/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (45.26 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/de/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (44.3 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/et/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (75.56 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/el/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_el.pdf)

français (FR) (44.73 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/fr/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (65.09 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/hr/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (45.28 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/is/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_is.pdf)

italiano (IT) (45.04 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/it/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.82 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/lv/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (62.93 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/lt/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.6 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/hu/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (69.45 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/mt/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (43.96 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/nl/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.17 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/no/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_no.pdf)

polski (PL) (68.33 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/pl/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.46 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/pt/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_pt.pdf)

română (RO) (67.43 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/ro/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (64.85 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sk/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (53.49 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sl/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (44.18 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/fi/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.05 KB - PDF)

**First published:**

05/03/2021

**Last updated:**

24/10/2024

[View](/sv/documents/all-authorised-presentations/onbevzi-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Onbevzi Active substance bevacizumab International non-proprietary name (INN) or common name bevacizumab Therapeutic area (MeSH)

- Colorectal Neoplasms
- Breast Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms

Anatomical therapeutic chemical (ATC) code L01FG01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

Onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.

Onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Onbevzi in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.

Onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.

Onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.

Onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.

Onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents.

Onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents.

Onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

## Authorisation details

EMA product number EMEA/H/C/005640

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Samsung Bioepis NL B.V.

Olof Palmestraat 10 2616 LR Delft The Netherlands

Opinion adopted 12/11/2020 Marketing authorisation issued 11/01/2021 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Onbevzi : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (191.36 KB - PDF)

**First published:** 18/05/2021

**Last updated:** 24/10/2024

[View](/en/documents/procedural-steps-after/onbevzi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Onbevzi-H-C-PSUSA-00000403-202202 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/921971/2022

English (EN) (171.88 KB - PDF)

**First published:** 05/01/2023

**Last updated:** 24/10/2024

[View](/en/documents/scientific-conclusion/onbevzi-h-c-psusa-00000403-202202-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Onbevzi : EPAR - Public assessment report

Adopted

Reference Number: EMA/117409/2021

English (EN) (10.51 MB - PDF)

**First published:** 05/03/2021

**Last updated:** 24/10/2024

[View](/en/documents/assessment-report/onbevzi-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Onbevzi

Adopted

Reference Number: EMA/CHMP/576998/2020

English (EN) (189.44 KB - PDF)

**First published:** 13/11/2020

**Last updated:** 24/10/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-onbevzi_en.pdf)

#### News on Onbevzi

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020) 13/11/2020

#### Related content

- [Biosimilar medicines: Overview](/en/human-regulatory-overview/biosimilar-medicines-overview)

**This page was last updated on** 24/10/2024

## Share this page

[Back to top](#main-content)